{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T09:47:03Z","timestamp":1773827223285,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Shandong Provincial Medical and Health Science and Technology Development Program","award":["2018WS569"],"award-info":[{"award-number":["2018WS569"]}]},{"name":"Shandong Provincial Medical and Health Science and Technology Development Program","award":["202304080192"],"award-info":[{"award-number":["202304080192"]}]},{"name":"Shandong Provincial Medical and Health Science and Technology Development Program","award":["202101040677"],"award-info":[{"award-number":["202101040677"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"DOI":"10.1186\/s13000-025-01726-y","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:28:23Z","timestamp":1760614103000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical significance and expression of ALDH1 in triple-negative breast cancer"],"prefix":"10.1186","volume":"20","author":[{"given":"Yaoyao","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoran","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangyang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chongyong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7603-1489","authenticated-orcid":false,"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"1726_CR1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17071183","volume":"17","author":"M Pajewska","year":"2025","unstructured":"Pajewska M, et al. Advanced and metastatic triple negative breast cancer\u2014potential new treatment. Cancers. 2025;17:1183.","journal-title":"Cancers"},{"key":"1726_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"1726_CR3","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1002\/cncr.27581","volume":"118","author":"NU Lin","year":"2012","unstructured":"Lin NU, et al. Clinicopathological features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer. 2012;118:5463\u201372.","journal-title":"Cancer"},{"key":"1726_CR4","volume":"15","author":"Y Li","year":"2022","unstructured":"Li Y, et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 2022;15:121.","journal-title":"J Hematol Oncol"},{"key":"1726_CR5","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2147\/IJWH.S178349","volume":"11","author":"J Mehanna","year":"2019","unstructured":"Mehanna J, Haddad FG, Eid R, Lambertini M, Kourie HR. Triple-negative breast cancer: current perspective on the evolving therapeutic landscape. Int J Womens Health. 2019;11:431\u20137.","journal-title":"Int J Womens Health"},{"key":"1726_CR6","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.canlet.2021.09.038","volume":"523","author":"M Xia","year":"2021","unstructured":"Xia M, Zu X, Chen Z, Wen G, Zhong J. Noncoding RNAs in triple negative breast cancer: mechanisms for chemoresistance. Cancer Lett. 2021;523:100\u201310.","journal-title":"Cancer Lett"},{"key":"1726_CR7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"G Bianchini","year":"2022","unstructured":"Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol. 2022;19:91\u2013113.","journal-title":"Nat Rev Clin Oncol"},{"key":"1726_CR8","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/emboj.2013.97","volume":"32","author":"C Vicente-Due\u00f1as","year":"2013","unstructured":"Vicente-Due\u00f1as C, Romero-Camarero I, Cobaleda C, S\u00e1nchez-Garc\u00eda I. Function of oncogenes in cancer development: a changing paradigm. EMBO J. 2013;32:1502\u201313.","journal-title":"EMBO J"},{"key":"1726_CR9","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1158\/2159-8290.CD-15-0327","volume":"5","author":"MD Brooks","year":"2015","unstructured":"Brooks MD, Wicha MS. Tumor twitter: cellular communication in the breast cancer stem cell niche. Cancer Discov. 2015;5:469\u201371.","journal-title":"Cancer Discov"},{"key":"1726_CR10","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.stemcr.2013.11.009","volume":"2","author":"S Liu","year":"2013","unstructured":"Liu S, et al. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Rep. 2013;2:78\u201391.","journal-title":"Stem Cell Rep"},{"key":"1726_CR11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.semradonc.2018.10.003","volume":"29","author":"M Luo","year":"2019","unstructured":"Luo M, Wicha MS. Targeting cancer stem cell redox metabolism to enhance therapy responses. Semin Radiat Oncol. 2019;29:42\u201354.","journal-title":"Semin Radiat Oncol"},{"issue":"1","key":"1726_CR12","volume":"10","author":"SG Pai","year":"2017","unstructured":"Pai SG, et al. Wnt\/beta-catenin pathway: modulating anticancer immune response. J Hematol Oncol. 2017;10(1):101.","journal-title":"J Hematol Oncol"},{"key":"1726_CR13","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ncb3041","volume":"16","author":"H Lu","year":"2014","unstructured":"Lu H, et al. A breast cancer stem cell niche supported by juxtacrine signaling from monocytes and macrophages. Nat Cell Biol. 2014;16:1105\u201317.","journal-title":"Nat Cell Biol"},{"key":"1726_CR14","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-13-3292","volume":"20","author":"C Shao","year":"2014","unstructured":"Shao C, et al. Essential role of aldehyde dehydrogenase 1A3 (ALDH1A3) for the maintenance of non-small cell lung cancer stem cells is associated with the STAT3 pathway. Clin Cancer Res Off J Am Assoc Cancer Res. 2014;20:4154\u201366.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"1726_CR15","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/stem.1193","volume":"30","author":"Y Luo","year":"2012","unstructured":"Luo Y, et al. ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells. 2012;30:2100\u201313.","journal-title":"Stem Cells"},{"key":"1726_CR16","doi-asserted-by":"crossref","first-page":"7219","DOI":"10.1158\/0008-5472.CAN-15-2860","volume":"76","author":"P Cheng","year":"2016","unstructured":"Cheng P, et al. FOXD1-ALDH1A3 signaling is a determinant for the self-renewal and tumorigenicity of mesenchymal glioma stem cells. Cancer Res. 2016;76:7219\u201330.","journal-title":"Cancer Res"},{"key":"1726_CR17","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1158\/1078-0432.CCR-15-1800","volume":"22","author":"M-H Chen","year":"2016","unstructured":"Chen M-H, et al. ALDH1A3, the major aldehyde dehydrogenase isoform in human cholangiocarcinoma cells, affects prognosis and gemcitabine resistance in cholangiocarcinoma patients. Clin Cancer Res. 2016;22:4225\u201335.","journal-title":"Clin Cancer Res"},{"key":"1726_CR18","doi-asserted-by":"crossref","first-page":"22325","DOI":"10.18632\/oncotarget.16479","volume":"8","author":"KE Sullivan","year":"2017","unstructured":"Sullivan KE, Rojas K, Cerione RA, Nakano I, Wilson KF. The stem cell\/cancer stem cell marker ALDH1A3 regulates the expression of the survival factor tissue transglutaminase, in mesenchymal glioma stem cells. Oncotarget. 2017;8:22325\u201343.","journal-title":"Oncotarget"},{"key":"1726_CR19","first-page":"193","volume":"49","author":"X Xu","year":"2025","unstructured":"Xu X, et al. A self-accelerating \u2018copper bomb\u2019 strategy activated innate and adaptive immune response against triple-negative breast cancer. Bioact Mater. 2025;49:193\u2013206.","journal-title":"Bioact Mater"},{"key":"1726_CR20","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-024-02574-4","volume":"42","author":"DY Lestari","year":"2024","unstructured":"Lestari DY, Mastutik G, Mukono IS. Betulinic acid and oleanolic acid modulate CD81 expression and induce apoptosis in triple-negative breast cancer cells through ROS generation. Med Oncol. 2024;42:24.","journal-title":"Med Oncol"},{"key":"1726_CR21","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.cmet.2024.07.011","volume":"36","author":"G Li","year":"2024","unstructured":"Li G, et al. Glycometabolic reprogramming-induced XRCC1 lactylation confers therapeutic resistance in ALDH1A3-overexpressing glioblastoma. Cell Metab. 2024;36:1696-1710.e10.","journal-title":"Cell Metab"},{"key":"1726_CR22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.molonc.2014.07.010","volume":"9","author":"P Marcato","year":"2015","unstructured":"Marcato P, et al. Aldehyde dehydrogenase 1A3 influences breast cancer progression via differential retinoic acid signaling. Mol Oncol. 2015;9:17\u201331.","journal-title":"Mol Oncol"},{"key":"1726_CR23","volume":"14","author":"J Bu","year":"2023","unstructured":"Bu J, et al. Kk-lc-1 as a therapeutic target to eliminate ALDH+ stem cells in triple negative breast cancer. Nat Commun. 2023;14:2602.","journal-title":"Nat Commun"},{"key":"1726_CR24","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.stem.2007.08.014","volume":"1","author":"C Ginestier","year":"2007","unstructured":"Ginestier C, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1:555\u201367.","journal-title":"Cell Stem Cell"},{"key":"1726_CR25","volume":"8","author":"\u00c1 Nagy","year":"2018","unstructured":"Nagy \u00c1, L\u00e1nczky A, Menyh\u00e1rt O, Gy\u0151rffy B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep. 2018;8:9227.","journal-title":"Sci Rep"},{"key":"1726_CR26","volume":"19","author":"J Zhang","year":"2024","unstructured":"Zhang J, Liu S, Wu M, Shi W, Cai Y. Clinical significance and expression of SLC35F6 in bladder urothelial carcinoma. Diagn Pathol. 2024;19:150.","journal-title":"Diagn Pathol"},{"key":"1726_CR27","doi-asserted-by":"crossref","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","volume":"10","author":"RL Camp","year":"2004","unstructured":"Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252\u20139.","journal-title":"Clin Cancer Res"},{"key":"1726_CR28","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2559.2011.03884.x","volume":"59","author":"Y Ohi","year":"2011","unstructured":"Ohi Y, et al. Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer. Histopathology. 2011;59:776\u201380.","journal-title":"Histopathology"},{"key":"1726_CR29","volume":"96","author":"F Ma","year":"2017","unstructured":"Ma F, et al. Aldehyde dehydrogenase 1 (ALDH1) expression is an independent prognostic factor in triple negative breast cancer (TNBC). Medicine (Baltimore). 2017;96:e6561.","journal-title":"Medicine (Baltimore)"},{"key":"1726_CR30","volume":"96","author":"J Yao","year":"2017","unstructured":"Yao J, Jin Q, Wang X-D, Zhu H-J, Ni Q-C. Aldehyde dehydrogenase 1 expression is correlated with poor prognosis in breast cancer. Medicine (Baltimore). 2017;96:e7171.","journal-title":"Medicine (Baltimore)"},{"key":"1726_CR31","doi-asserted-by":"crossref","first-page":"41360","DOI":"10.18632\/oncotarget.6023","volume":"6","author":"Y Liu","year":"2015","unstructured":"Liu Y, et al. ALDH1A1 mRNA expression in association with prognosis of triple-negative breast cancer. Oncotarget. 2015;6:41360\u20139.","journal-title":"Oncotarget"},{"key":"1726_CR32","doi-asserted-by":"crossref","first-page":"313","DOI":"10.17305\/bjbms.2018.3094","volume":"18","author":"H Demir","year":"2018","unstructured":"Demir H, Dulgar O, Gulle BT, Turna H, Ilvan S. Prognostic value of aldehyde dehydrogenase 1 (ALDH1) in invasive breast carcinomas. Bosn J Basic Med Sci. 2018;18:313\u20139.","journal-title":"Bosn J Basic Med Sci"},{"key":"1726_CR33","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.stem.2007.08.014","volume":"1","author":"C Ginestier","year":"2007","unstructured":"Ginestier C, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1:555\u201367.","journal-title":"Cell Stem Cell"},{"key":"1726_CR34","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/jcp.2011.090456","volume":"64","author":"S Ricardo","year":"2011","unstructured":"Ricardo S, et al. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol. 2011;64:937\u201346.","journal-title":"J Clin Pathol"},{"key":"1726_CR35","doi-asserted-by":"crossref","first-page":"35205","DOI":"10.18632\/oncotarget.16925","volume":"8","author":"G Bousquet","year":"2017","unstructured":"Bousquet G, et al. Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer. Oncotarget. 2017;8:35205\u201321.","journal-title":"Oncotarget"},{"key":"1726_CR36","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-05220-6","volume":"9","author":"AS Cazet","year":"2018","unstructured":"Cazet AS, et al. Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer. Nat Commun. 2018;9:2897.","journal-title":"Nat Commun"},{"key":"1726_CR37","volume":"14","author":"J Bu","year":"2023","unstructured":"Bu J, et al. Kk-lc-1 as a therapeutic target to eliminate ALDH+ stem cells in triple negative breast cancer. Nat Commun. 2023;14:2602.","journal-title":"Nat Commun"},{"key":"1726_CR38","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/cac2.12429","volume":"43","author":"S Ding","year":"2023","unstructured":"Ding S, et al. Single-cell atlas reveals a distinct immune profile fostered by T cell-B cell crosstalk in triple negative breast cancer. Cancer Commun. 2023;43:661\u201384.","journal-title":"Cancer Commun"},{"key":"1726_CR39","volume":"21","author":"Y Zheng","year":"2023","unstructured":"Zheng Y, et al. A diagnostic model for sepsis-induced acute lung injury using a consensus machine learning approach and its therapeutic implications. J Transl Med. 2023;21:620.","journal-title":"J Transl Med"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-025-01726-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13000-025-01726-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-025-01726-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:28:34Z","timestamp":1760614114000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/s13000-025-01726-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1726"],"URL":"https:\/\/doi.org\/10.1186\/s13000-025-01726-y","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained prior to tissue collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"117"}}